In the current studies, limited serum biomarkers, such as the ratio of free to total PSA (f/T), prostatic-specific antigen density (PSAD), and urine spermine, have been used to help improve the diagnosis rate of PCa with PSA levels between 4 and 20 ng/ml (13–15). This evidence concerns the gene KLK3 and posterior cortical atrophy.